title: Targeting tumours with genetically enhanced T lymphocytes.
abstract: The genetic modification of T lymphocytes is an important approach to investigating normal T-cell biology and to increasing antitumour immunity. A number of genetic strategies aim to increase the recognition of tumour antigens, enhance antitumour activities and prevent T-cell malfunction. T cells can also be engineered to increase safety, as well as to express markers that can be tracked by non-invasive imaging technologies. Genetically modified T cells are therefore proving to be of great value for basic immunology and experimental immunotherapy.
authors.affiliation: Department of Medicine and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. m-sadelain@ski.mskcc.org
authors.forename: Michel
authors.initials: M
authors.lastname: Sadelain
authors.forename: Isabelle
authors.initials: I
authors.lastname: Rivière
authors.forename: Renier
authors.initials: R
authors.lastname: Brentjens
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D011948:Receptors, Antigen, T-Cell